Cardiol Therapeutics Inc.
TSX:CRDL.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $164.10M
- Beta
- 0.48
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.08M
Average 0.12M
CRDL.TO Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Cardiol Therapeutics Inc.TSX: CRDL.TO
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was CA$0, compared with CA$0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
CAD · from the balance sheet
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How CRDL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 0.0% of total assets for CRDL.TO, versus a peer median of 34.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $51.25M USD | +498.3% | — | 68.1% |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CRDL.TO) | — | +498.3% | — | 34.0% | |
Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83.9M | 59.47M | 34.93M | 30.58M | 21.42M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 407.13K | 480.2K | 279.87K | 361.62K | 226.2K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 87.14M | 61.44M | 36.15M | 31.67M | 23.5M |
| Property, Plant & Equipment (Net) | 356.49K | 295.74K | 337.06K | 195.59K | 118.09K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 379.25K | 294.8K | 210.36K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | (0) | 0 | 0 | 0 |
| Total Non-current Assets | 735.74K | 590.54K | 547.42K | 195.59K | 118.09K |
| Total Assets | 87.88M | 62.03M | 36.7M | 31.86M | 23.62M |
| Account Payables | 4.19M | 8.35M | 0 | 6.98M | 0 |
| Short-term Debt | 0 | 0 | 0 | 33.01K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | (4.19M) | (8.35M) | 0 | 0 | 0 |
| Other Current Liabilities | 7.33M | 1.4M | 8.3M | (33.01K) | 5.62M |
| Total Current Liabilities | 11.57M | 9.8M | 8.3M | 7.01M | 5.66M |
| Long-term Debt | 0 | 0 | 158.53K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | (158.53K) | 0 | 0 |
| Total Non-current Liabilities | 72.87K | 22.42K | 158.53K | 125.52K | 87.18K |
| Total Liabilities | 11.64M | 9.83M | 8.45M | 7.14M | 5.74M |
| Common Stock | 142.92M | 147.55M | 148.52M | 179.34M | 201.87M |
| Retained Earnings | (83.52M) | (114.45M) | (142.58M) | (179.25M) | (213.07M) |
| Accumulated OCI | 4.18M | 3.52M | 3.52M | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 136 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 76.24M | 52.2M | 28.25M | 24.73M | 17.88M |
| Total Debt | 117.58K | 72.87K | 158.53K | 158.53K | 125.52K |
| Net Debt | (83.78M) | (59.4M) | (34.77M) | (30.42M) | (21.29M) |
Cardiol Therapeutics Inc.
TSX:CRDL.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.